The PennZone

  • Home
  • Business
  • Health
  • Financial
  • Entertainment
  • Education
  • Legal
  • Construction
  • Non-profit

CPC Scientific Announces New California Peptide API Manufacturing Facility
The PennZone/10188374

Trending...
  • Psychologist-Turned-Hermeticist Releases Modern Guide to the Seven Hermetic Principles
  • Winners Announced for Asia Pacific Business Awards 2024-2025
  • Preliminary.online Introduces Short-Term Job-Readiness Courses with Employer-Verified Certifications
CPC Scientific Inc.
SAN JOSE, Calif. - PennZone -- CPC Scientific Inc., a leading global peptide CRDMO (Contract Research, Development, and Manufacturing Organization) has invested in a new peptide API (Active Pharmaceutical Ingredient) manufacturing site, bringing many new jobs to Rocklin, California. The 41,000 sq ft facility located at 3880 Atherton Rd, Rocklin, CA 95765 will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity and will diversify CPC Scientific's supply chain.

"CPC Scientific is entering an exciting period of growth and innovation for peptide and oligonucleotide therapeutic development and manufacturing, and we will continue to provide therapeutic APIs to pharmaceutical and biotech companies around the world. We are very pleased to partner with the City of Rocklin, California to bring manufacturing and Life-Science jobs to local American workers," said Shawn Lee, Ph.D., CEO.

Expanding CPC Scientific's manufacturing footprint in North America enables them to continue to produce innovative peptide products while providing additional capacity to specialty peptide APIs more rapidly.

More on The PennZone
  • West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
  • Germantown Fashion & Arts Festival 2025 Draws Thousands, Celebrates Creativity in Historic Philly
  • The AML Shop Launches New Financial Investigations Unit, Appoints Director to Lead the Initiative
  • Casting Pro Darya Balyura Named Judge for 2025 Meals 4 Monologues Virtual Showcase
  • Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild

Peptide-based therapeutic candidates have been the fastest growing sector among all the chemical synthesized NCEs (New Chemical Entities) for new drug development in recent years. For over two decades, CPC Scientific has been a reliable partner for its clients all over the world including multinational pharmaceutical companies, biotech companies, and academic institutions by providing value-added one-stop-shop development and manufacturing services to support their clinical trials. CPC Scientific has been successfully supplying commercialized APIs to their clients in the U.S., Europe, Australia, Japan, and China for their peptide-based drugs and medical devices. By expanding their GMP manufacturing footprint, the CRDMO will enable their clients and partners to have multiple geographic options to ensure a secure API supply chain.

"We have helped many of our clients to bring an innovative drug into the market from a concept. With the new Rocklin site, we believe we will be able to contribute more especially to the Northern American market and we will continue making our efforts with our decades of peptide synthesis expertise to help our clients to save lives and improve human health worldwide," said Shawn Lee, Ph.D.

More on The PennZone
  • New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
  • The Herbal Care, Led by Markel Bababekov, Becomes a Top Dispensary in NYC's Upper East Side
  • Digital Watchdog Launches New myDW Cloud Services
  • Stan Fitzgerald Appointed Acting Press Secretary for Veterans for America First VFAF Georgia State Chapter
  • Drone Light Shows Emerge as the New Standard in Live Event Entertainment

The new Rocklin CGMP facility is scheduled to be online and fully operational by 2023. With manufacturing operations in Hangzhou (CN) and Rocklin, CA (US), these facilities will enable CPC Scientific to help meet the growing worldwide demand for peptide-based therapeutics and diagnostics.

About CPC Scientific.

Founded in 2001, CPC Scientific is a globally recognized and leading CRDMO specializing in synthetic peptide production, which is also expanding its footprint in synthetic oligonucleotides. The company works directly with leaders in the biotechnology and pharmaceutical industries to help bring life-changing therapeutics and diagnostics to market. CPC Scientific has the capability of serving customers from early drug discovery stages through clinical trials to commercial manufacturing and is proudly supplying commercial APIs to our partners all over the world. Dozens of isolated process and purification suites for peptide manufacturing enable simultaneous multi-Kg batch size projects. With an emphasis on technology, innovation, and experience, we are proud to have facilities inspected by many government agencies including U.S. Food and Drug Administration (FDA).

Contact
Chris Gothard, Ph.D.
***@cpcscientific.com
408-734-3800


Source: CPC Scientific Inc.

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Berger Montague Investigates Securities Class Action Against Hims & Hers Health Inc. (NYSE: HIMS)
  • Michael Reafsnyder opens solo exhibition at Scott Richards Contemporary Art in San Francisco
  • Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
  • $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
  • $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
  • #ChipInChipAway at Hunger Taking Place on July 10th, 2025
  • Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
  • Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
  • Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
  • Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
  • INVESTIGATION ALERT: Berger Montague PC Investigates Aflac, Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: AFL)
  • AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
  • The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence
  • $796,000 in Q2 Revenue Marks Highest Earnings to Date on 3 Trailing Quarters of Profitability in Multi-Billion Homebuilding Sector: Stock Symbol: IVDN
  • Cybersecurity is THE Hot Market Sector; Revenues, Earnings & Profit matter; Only 33 Million Shares + a Huge Short Position Equal an Undervalued Stock
  • Despite Global Calls for a Ban, US Child Psychiatry Pushes Electroshock for Kids
  • BeyondTrucks CEO Wins Gold Stevie® Award for Best Entrepreneur in Transportation
  • Franco Polished Plaster Celebrates 35 Years of Bringing Walls to Life in the UK
  • Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
  • C8C.AI Launches Audio Compliance Engine to Streamline Ethical AI Audio Data at Scale

Popular on PennZone

  • Real Estate CEO Launches Explosive New Book After $275,784 Wire Fraud Incident - 102
  • JMC Princess Announces Release of Empowering New Single "PRETTY" – A Summer Anthem for Young Girls Everywhere
  • TEDxInglewood Returns to The Miracle Theater on August 9, 2025 — Celebrating Bold Ideas and Community Energy
  • Manhattan Boutique Real Estate Collaborates with InterContinental Hotels NYC in a Branding Partners Personalized Approach
  • BREAKING CONSUMER ALERT: Carvana's "Certified" Luxury SUV Buyer Exposes Legal & Mechanical Trauma 'Presses' Charges of Duress, Deception, and Delay
  • INVESTIGATION ALERT: Berger Montague PC Investigates Coinbase Global, Inc.'s Board Of Directors For Breach of Fiduciary Duties (NASDAQ: COIN)
  • INVESTIGATION ALERT: Berger Montague PC Investigates Coinbase Global, Inc.'s Board Of Directors For Breach of Fiduciary Duties (NASDAQ: COIN)
  • Imagen Golf Announces New Partnership with The Hurricane Golf Tour
  • Let's Talk Series: At the Crossroads: Immigration Today
  • First AI Marketing Platform Built Specifically for Small Businesses Launches Public Beta

Similar on PennZone

  • New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient
  • $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
  • West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
  • Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
  • New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
  • Digital Watchdog Launches New myDW Cloud Services
  • Skyline Partners with ZenSpace to Offer Private Meeting Pods for Trade Show Exhibitors
  • AI Innovation Dual-Strategy Business Model Focused on Real Estate Development for Strategic Expansion: OFA Group, (N A S D A Q: OFAL)
  • Retired Hobbyist Launches Bold Weekly Album Project Using AI Songwriting Tools
  • Eolian Signs New Information Exchange Agreement with the U.S. Department of Defense for Technology Innovation
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us